트립신 시장 규모, 점유율, 동향 분석 보고서 : 공급원별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Trypsin Market Growth & Trends:

The global trypsin market size is estimated to reach USD 131.5 billion by 2030, registering a CAGR of 5.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing adoption of trypsin across various industries, such as pharmaceuticals, food science research, detergents, and leather-bating, is likely to drive the market growth. Where as various research studies are being conducted to evaluate its potential in diagnosing a wide range of disorders, such as cancer, acute pancreatitis, malabsorption, and cystic fibrosis, along with increasing focus on drug discovery and development is expected to further propel the market growth.

Trypsin is widely being used in R&D in pharmaceutical, food, and environmental industries, owing to its special digestive functions of hydrolyzing proteins. It acts as a raw material for internal medicine in endocrine diseases and clinical surgery. The use of enzyme catalysts has been scaled up for commercial processes in the pharmaceutical, beverages, and food industries. These enzymes help in waste reduction, which makes them highly efficient to be used in food, pharmaceuticals, and feed industries. Moreover, the best source of trypsin, TRYPSIN VI, has found nutraceutical use as an anti-inflammatory treatment and a digestive supplement for veterinary & human applications.

Various research studies are being conducted to evaluate its potential in diagnosing a wide range of disorders, such as cancer, acute pancreatitis, malabsorption, and cystic fibrosis. Increase in R&D expenditure, the rising drug launches, and FDA approvals.

Trypsin Market Report Highlights:

• Based on source, the bovine segment led the market with the largest revenue share of 59.71% in 2024, owing to prominent application in field of clinical diagnostics, research, food and beverage industry and meat tenderization
• Based on source, the porcine segment is expected to grow at the significant CAGR over the forecast period
• Based on application, the biotechnology and pharmaceutical industry segment held the market with the largest revenue share of 56.40% in 2024, and is further anticipated to witness the fastest CAGR over the forecast period. The increasing focus on drug discovery and development is further propelling growth
• North America dominated the market with the largest revenue share of 40.49% in 2024, owing to factors such as increasing the prevalence of various cancer, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
• In Dec 2023, Creative Enzymes, a global pioneer in professional enzyme related products and services unveiled its combination product offerings for proteolytic enzymes such as Trypsin-Chymotrypsin, with this company aims at optimizing the speed and efficiency of the digestive process opening new possibilities for medical and pharmaceutical enhancements.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1 Source
  • 1.2.2 Application
  • 1.2.3 end use
  • 1.2.4 Regional scope
  • 1.2.5 Estimates and forecasts timeline.
• 1.3. Research methodology
• 1.4. Information Procurement
  • 1.4.1 Purchased database
  • 1.4.2 GVR's internal database
  • 1.4.3 Secondary sources
  • 1.4.4 Primary research
  • 1.4.5 Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1 Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1 Commodity flow analysis (Model 1)
  • 1.7.2 Approach 1: Commodity flow approach
  • 1.7.3 Volume price analysis (Model 2)
  • 1.7.4 Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1 Source outlook
  • 2.2.2 Application outlook
  • 2.2.3 end use outlook
  • 2.2.4 Regional outlook
• 2.3. Competitive Insights

Chapter 3. Trypsin Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 1.3.1 Parent market outlook
  • 2.3.1 Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1 Market driver analysis
    • 3.2.1.1. Rising prevalence of gastrointestinal disorders
    • 3.2.1.2. Increasing trypsin related studies and therapeutics
    • 3.2.1.3. Technological advancements
  • 3.2.2 Market restraint analysis
    • 3.2.2.1. Stringent regulations
    • 3.2.2.2. High cost of sourcing
• 3.3. Trypsin Market Analysis Tools
  • 3.3.1 Industry Analysis - Porter's
  • 3.3.1 PESTEL Analysis

Chapter 4. Trypsin Market: Source Estimates & Trend Analysis

• 4.1. Global Trypsin: Source Dashboard
• 4.2. Global Trypsin: Source Movement Analysis 2024 & 2030
• 4.3. Global Trypsin by Source, Revenue 2018 - 2030 (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Porcine
  • 4.5.1 Porcine Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Bovine
  • 4.6.1 Bovine Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1 Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Trypsin Market: Application Estimates & Trend Analysis

• 5.1. Global Trypsin: Application Dashboard
• 5.2. Global Trypsin: Application Movement Analysis 2024 & 2030
• 5.3. Global Trypsin by Application, Revenue 2018 - 2030 (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Biotechnology and Pharmaceutical Industry
  • 5.5.1 Biotechnology and Pharmaceutical Industry Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Food Industry
  • 5.6.1 Food Industry Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Cosmetics and Personal Care
  • 5.7.1 Cosmetics and Personal Care Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Waste Treatment
  • 5.8.1 Waste Treatment Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1 Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Trypsin Market: end use Estimates & Trend Analysis

• 6.1. Global Trypsin: end use Dashboard
• 6.2. Global Trypsin: end use Movement Analysis 2024 & 2030
• 6.3. Global Trypsin by end use, Revenue 2018 - 2030 (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Research
  • 6.5.1 Research Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Diagnostics
  • 6.6.1 Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Industrial use
  • 6.7.1 Industrial use Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Trypsin Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1 North America
  • 7.5.2 U.S.
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3 Canada
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4 Mexico
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1 Europe
  • 7.6.2 UK
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3 Germany
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4 France
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5 Italy
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6 Spain
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7 Norway
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8 Sweden
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.9 Denmark
    • 7.6.9.1. Key country dynamics
    • 7.6.9.2. Regulatory framework
    • 7.6.9.3. Competitive scenario
    • 7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1 Asia Pacific
  • 7.7.2 Japan
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3 China
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4 India
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5 Australia
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6 South Korea
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.7 Thailand
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Regulatory framework
    • 7.7.7.3. Competitive scenario
    • 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1 Latin America
  • 7.8.2 Brazil
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3 Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1 MEA
  • 7.9.2 South Africa
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3 Saudi Arabia
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4 UAE
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.5 Kuwait
    • 7.9.5.1. Key country dynamics
    • 7.9.5.2. Regulatory framework
    • 7.9.5.3. Competitive scenario
    • 7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1 List of key distributors and channel partners
  • 8.3.2 Key customers
  • 8.3.3 Key company market share analysis, 2024
  • 8.3.4 Thermo Fisher Scientific, Inc
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Source benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5 Promega Corporation
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Source benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6 Merck Millipore
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Source benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7 Novozymes
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Source benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8 Sartorius AG
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Source benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Neova Technologies
    • 8.3.9.6. Company overview
    • 8.3.9.7. Financial performance
    • 8.3.9.8. Source benchmarking
    • 8.3.9.9. Strategic initiatives
  • 8.3.10 BIOZYM
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Source benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11 Bovogen Biologicals
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Source benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12 Zymetech
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Source benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13 BBI Solutions
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Source benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14 Linzyme Biosciences
    • 8.3.14.1. Company Overview
    • 8.3.14.2. Financial Performance
    • 8.3.14.3. Source Benchmarking
    • 8.3.14.4. Strategic Initiatives
  • 8.3.15 PromoCell GmbH.
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial Performance
    • 8.3.15.3. Source Benchmarking
    • 8.3.15.4. Strategic Initiatives